Kaitlyn D’Onofrio

DocwireNews

A study compared healthcare costs among psoriasis (PsO) patients initiating <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/ixekizumab-vs-adalimumab-for-psa-a-drug-comparison/">ixekizumab</a> compared to either secukinumab or <a href="https://www.docwirenews.com/abstracts/rheumatology-abstracts/comparison-of-health-care-costs-among-patients-with-psoriasis-initiating-ixekizumab-secukinumab-or-adalimumab/">adalimumab</a>.&ldquo;As more biologics become available for the treatment of psoriasis (PsO), there is a lack of direct comparisons of health care costs between patients who are treated by different medications, including ixekizumab (IXE), secukinumab (SEC), and adalimumab (ADA),&rdquo; the researchers proposed.The study authors used the IBM MarketScan commercial and Medicare databases to identify patients who received a PsO diagnosis between July 1, 2015, and May 31, 2018; they used this data to further create two patient datasets based on drug claims made between March 1, 2016, and May 31, 2018: ixekizumab versus secukinumab and ixekizumab versus adalimumab. Eligible patients were aged 18 years or older and had at least one year of continuous eligibility prior to and following the index date; those with other indications for the index drug in the preiperiod or with use of the index drug during the 90 days leading up to the index date were excluded from the study. The groups were balanced using inverse probability of treatment weighting (IPTW). Outcomes included all-cause and PsO-related healthcare costs per member per month (PMPM) incurred during one year of follow-up. Monthly costs related to PsO were adjusted using drug discount rates per the Institute for Clinical and Economic Review; annual index drug costs were determined by factoring n medication possession ratio and ICER discount rates.The two datasets included 357 ixekizumab patients compared to 763 secukinumab patients, and 388 ixekizumab patients compared to 2,578 adalimumab patients. Ixekizumab patients had similar demographic and clinical characteristics to the secukinumab patients, but compared to adalimumab patients, they were in worse health and had older age; postweighting was used to balance out any differences. Mean monthly all-cause healthcare costs were $7,313 for ixekizumab patients and $6,477 for secukinumab patients (P=0.002); mean PsO-related costs were $6,303 and $5,437 (P&lt;0.001), respectively. In the ixekizumab and adalimumab comparisons, mean monthly all-cause healthcare costs were $6,535 and $5,557 (P=0.026), respectively, and mean PsO-related sots were $5,792 and $4,754 (P=0.017), respectively. When ICER adjustments were implemented, mean monthly PsO-related costs did not largely differ between the groups in either dataset: ixekizumab versus secukinumab, $3,637 versus $3,443 (P=0.132), respectively; and ixekizumab versus adalimumab, $3,320 versus $3,287 (P=0.907), respectively.The findings were published in the <a href="https://www.jmcp.org/doi/10.18553/jmcp.2019.25.12.1366">Journal of Managed Care &amp; Specialty Pharmacy</a>.&ldquo;After adjusting for drug discount programs (through application of ICER discount rate), this real-world study estimated that average monthly PsO-related costs during the first year of treatment were similar between patients treated with IXE compared with those treated with SEC or ADA,&rdquo; the study authors summarized.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Ixekizumab, Secukinumab, and Adalimumab: A Healthcare Cost Analysis

Rheumatology

A study compared healthcare costs among psoriasis (PsO) patients initiating ixekizumab compared to either secukinumab or adalimumab. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe